Since the Q4 2019 reporting an additional 4 sites in US have been activated, meaning that 34 of the originally planned 40 sites in Europe and US are currently activated. In addition, PCI Biotech has made regulatory progress in the process of adding Asian sites into the RELEASE study, having secured recently regulatory approval in Taiwan
South korea next
The US patent to be granted in April 2020 gives broad coverage for the combination of TLR agonists with the fima Vacc technology.
This US patent is therefore important for PCI Biotechs partnering efforts and it also provides intellectual property of importance for our ability to potentially generate an internal future vaccine pipeline, said Per Walday, CEO of PCI Biotech.
Todays announced US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets.
Med disse meldingene og uten corona “rabatt” tipper jeg vi hadde ligget rundt 100kr aksjen idag.
#Arctic kursmål 86, uten disse 2 siste børsmeldingene